Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort
Authors:
- S. D. HolmbergSHS. D. Holmberg
- A. C. MoormanAMA. C. Moorman
- for the Chronic Hepatitis Cohort Study (CHeCS) InvestigatorsFIfor the Chronic Hepatitis Cohort Study (CHeCS) Investigators
- Eyasu H. TeshaleETEyasu H. Teshale
- Philip R. SpradlingPSPhilip R. Spradling
Open Access
- 16 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (2) , 240-246
Abstract
Background. Liver biopsy remains critical for staging liver disease in hepatitis C virus (HCV)–infected persons, but is a bottleneck to evaluation, follow-up, and treatment of HCV. Our analysis sought to validate APRI (aspartate aminotransferase [AST]–to-platelet ratio index) and FIB-4, an index from serum fibrosis markers (alanine aminotransferase [ALT], AST, and platelets plus patient age) to stage liver disease. Methods. Biopsy results from HCV patients in the Chronic Hepatitis Cohort Study were mapped to an F0–F4 equivalent scale; APRI and FIB-4 scores at the time of biopsy were then mapped to the same scale. Results. We identified 2372 liver biopsies from HCV-infected patients with contemporaneous laboratory values for imputing APRI and FIB-4. Fibrosis stage distributions by the equivalent biopsy scale were 267 (11%) F0; 555 (23%) F1; 648 (27%) F2; 394 (17%) F3; and 508 (21%) F4. Mean APRI and FIB-4 values significantly increased with successive fibrosis levels (P < .05). The areas under the receiver operating characteristic curve (AUROC) analysis distinguishing severe (F3–F4) from mild-to-moderate fibrosis (F0–F2) were 0.80 (95% confidence interval [CI], .78–.82) for APRI and 0.83 (95% CI, .81–.85) for FIB-4. There was a significant difference between the AUROCs of FIB-4 and APRI (P < .001); 88% of persons who had a FIB-4 score ≥2.0 were at stage F2 or higher. Conclusions. In a large observational cohort, FIB-4 was good at differentiating 5 stages of chronic HCV infection. It can be useful in screening patients who need biopsy and therapy, for monitoring patients with less advanced disease, and for longitudinal studies.Keywords
This publication has 32 references indexed in Scilit:
- Discordance Among Transient Elastography, Aspartate Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients With Chronic Hepatitis CClinical Gastroenterology and Hepatology, 2013
- Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection PrevalenceClinical Infectious Diseases, 2012
- Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 PatientsHepatitis Monthly, 2012
- Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and CLiver International, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- FIB-4Hepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Complications following percutaneous liver biopsyJournal of Hepatology, 1986